Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.2.1.68 - isoamylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis, Lactic
Tramadol poisoning with hyperamylasemia.
Biliary Tract Diseases
The pancreatic enzymes value in the diagnosis of acute pancreatitis and acute biliary tract diseases.
Breast Neoplasms
A unique case of breast carcinoma producing pancreatic-type isoamylase.
Pancreatic-type isoamylase in breast carcinoma.
Carcinoma
A prospective study of amylase-rich pleural effusions with special reference to amylase isoenzyme analysis.
Nonpancreatic-type hyperamylasemia associated with pancreatic cancer.
Unusual anodic migrating isoamylase differentiates selected malignant from nonmalignant ascites.
[Serum pancreatic enzymes in the diagnosis of carcinoma of the pancreas]
Carcinoma, Non-Small-Cell Lung
Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth.
Cardiomyopathies
Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.
Celiac Disease
Serum isoamylase activities in cystic fibrosis patients, determined by an inhibitory assay.
Cholangitis, Sclerosing
The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis.
Cholelithiasis
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Colonic Diseases
Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease.
Craniocerebral Trauma
Serum amylase and its isoenzymes: a clarification of their implications in trauma.
Crohn Disease
Hyperamylasemia in inflammatory bowel disease.
Cystic Fibrosis
Comparison of the diagnostic value of serum pancreatic isoamylase and immunoreactive trypsin measurement in patients with cystic fibrosis.
Cystic fibrosis serum pancreatic amylase. Useful discriminator of exocrine function.
Cystic fibrosis--its biochemical detection.
Isoamylase abnormalities in cystic fibrosis.
Letters to the editor: Isoamylase abnormalities in cystic fibrosis.
Serum immuno reactive trypsin and pancreatic isoamylase in older patients with cystic fibrosis.
Serum isoamylase activities in cystic fibrosis patients, determined by an inhibitory assay.
Serum pancreatic isoamylases in the diagnosis of cystic fibrosis heterozygotes: A non-valuable test.
Serum pancreatic lipase activity in cystic fibrosis.
Cysts
Isoamylases and their thermolability in serum and cyst fluid from patients with pancreatic pseudocysts.
Diabetes Mellitus
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Exocrine pancreatic function in diabetes mellitus.
Renal isoamylase clearance as a measure of altered renal charge selectivity in patients with diabetes mellitus.
Serum concentration of cathodic trypsin-like immunoreactivity and pancreatic isoamylase in insulin-dependent diabetes mellitus.
Serum isoamylase activities in diabetes mellitus.
Diabetes Mellitus, Type 1
Exocrine pancreatic function in insulin-dependent diabetes mellitus.
Glomerular charge selectivity in type 1 (insulin-dependent) diabetes mellitus.
Serum concentration of cathodic trypsin-like immunoreactivity and pancreatic isoamylase in insulin-dependent diabetes mellitus.
Serum lipase, isoamylase and pancreatic function test (PFT) in juvenile-onset insulin-dependent diabetes mellitus.
Duodenitis
[Pseudo acute pancreatitis: a syndrome mimicked by a multiple parasitic duodenitis. Analysis of 7 case]
Eosinophilia
[Pseudo acute pancreatitis: a syndrome mimicked by a multiple parasitic duodenitis. Analysis of 7 case]
Exocrine Pancreatic Insufficiency
Behaviour of serum pancreatic enzymes in chronic pancreatitis.
Comparative study of serum pancreatic isoamylase, lipase, and trypsin-like immunoreactivity in pancreatic disease.
Diagnostic and therapeutic applications of bentiromide screening test for exocrine pancreatic insufficiency in patients with cystic fibrosis. Comparison with other tests of exocrine pancreatic disease.
Estimation of serum pancreatic isoamylase: its role in the diagnosis of exocrine pancreatic insufficiency.
Fecal isoamylase activity in patients with pancreatic diseases.
Relation between serum pancreatic isoamylase concentration and pancreatic exocrine function.
Salivary isoamylase in duodenal aspirates.
Sensitivity and specificity of canine serum total amylase and isoamylase activity determinations.
Serum isoamylase as a test for pancreatic insufficiency.
Serum isoamylase values in normal dogs and dogs with exocrine pancreatic insufficiency.
Serum isoamylases in chronic pancreatitis.
Serum pancreatic isoamylase activity in pancreatic disease.
Value of pancreatic-type isoamylase assay as an index of pancreatic insufficiency.
Glomerulonephritis, Membranous
Glomerular charge selectivity in primary glomerulopathies.
Glycogen Storage Disease
A c.3216_3217delGA mutation in AGL gene in Tunisian patients with a glycogen storage disease type III: evidence of a founder effect.
A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series.
A mutation analysis of the AGL gene in Korean patients with glycogen storage disease type III.
A nonsense mutation due to a single base insertion in the 3'-coding region of glycogen debranching enzyme gene associated with a severe phenotype in a patient with glycogen storage disease type IIIa.
A novel donor splice site mutation in the glycogen debranching enzyme gene is associated with glycogen storage disease type III.
A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme.
A Novel Nonsense Mutation of the AGL Gene in a Romanian Patient with Glycogen Storage Disease Type IIIa.
A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb.
A single-base deletion in the 3'-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients.
Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa.
Biochemical and molecular investigation of two Korean patients with glycogen storage disease type III.
Characterization of a canine model of glycogen storage disease type IIIa.
Cognitive profile of patients with glycogen storage disease type III: a clinical description of seven cases.
Compound heterozygous patient with glycogen storage disease type III: identification of two novel AGL mutations, a donor splice site mutation of Chinese origin and a 1-bp deletion of Japanese origin.
Distinct Clinical and Genetic Findings in Iranian Patients With Glycogen Storage Disease Type 3.
Distinct mutations in the glycogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions.
DNA-based subtyping of glycogen storage disease type III: mutation and haplotype analysis of the AGL gene in Chinese.
Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time.
Expression of a Functional Recombinant Human Glycogen Debranching Enzyme (hGDE) in N. benthamiana Plants and in Hairy Root Cultures.
Expression of catalytically active human multifunctional glycogen-debranching enzyme and lysosomal acid alpha-glucosidase in insect cells.
Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease.
Glycogen Debrancher Enzyme Deficiency Myopathy.
Glycogen debranching enzyme: purification, antibody characterization, and immunoblot analyses of type III glycogen storage disease.
Glycogen storage disease type III: A novel Agl knockout mouse model.
Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.
Glycogen storage disease type IIIa in curly-coated retrievers.
Glycogen storage disease type IIIa presenting as non-ketotic hypoglycemia: use of a newly approved commercially available mutation analysis to non-invasively confirm the diagnosis.
Glycogen storage disease type IIIa: first report of a causative missense mutation (G1448R) of the glycogen debranching enzyme gene found in a homozygous patient.
Hepatic and neuromuscular forms of glycogenosis type III: nine mutations in AGL.
Heterogeneous mutations in the glycogen-debranching enzyme gene are responsible for glycogen storage disease type IIIa in Japan.
High frequency of W1327X mutation in glycogen storage disease type III patients from central Tunisia.
Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III.
Intron retention is among six unreported AGL mutations identified in Malaysian GSD III patients.
Involvement of glycogen debranching enzyme in bladder cancer.
Isolation and nucleotide sequence of human liver glycogen debranching enzyme mRNA: identification of multiple tissue-specific isoforms.
Leucocyte alpha-1,4- and alpha-1,6-glucosidase activities towards oligosaccharides in late onset glycogenosis type II.
Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa.
Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey.
Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with Glycogen Storage Disease Type III.
Molecular and biochemical characterization of a novel intronic single point mutation in a Tunisian family with glycogen storage disease type III.
Molecular and biochemical characterization of Tunisian patients with glycogen storage disease type III.
Molecular characterization of Egyptian patients with glycogen storage disease type IIIa.
Molecular characterization of glycogen storage disease type III.
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
Mouse model of glycogen storage disease type III.
Multidisciplinary management of an obstetric patient with glycogen storage disease type 3.
Mutation Analysis in Glycogen Storage Disease Type III Patients in the Netherlands: Novel Genotype-Phenotype Relationships and Five Novel Mutations in the AGL Gene.
Mutational analysis of the AGL gene: five novel mutations in GSD III patients.
Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III.
Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle.
Natural Progression of Canine Glycogen Storage Disease Type IIIa.
Polymorphic markers of the glycogen debranching enzyme gene allowing linkage analysis in families with glycogen storage disease type III.
Prenatal diagnosis and carrier detection for glycogen storage disease type III using polymorphic DNA markers.
Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis.
Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.
Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease.
Simultaneous absence of alpha-1,4-glucosidase and alpha-1,6-glucosidase activities (pH 4) in tissues of children with type II glycogen storage disease.
Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.
Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III.
Two new mutations in the 3' coding region of the glycogen debranching enzyme in a glycogen storage disease type IIIa Ashkenazi Jewish patient.
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]
[Molecular and clinical characterization of Colombian patients suffering from type III glycogen storage disease].
Glycogen Storage Disease Type II
Leucocyte alpha-1,4- and alpha-1,6-glucosidase activities towards oligosaccharides in late onset glycogenosis type II.
Glycogen Storage Disease Type III
A c.3216_3217delGA mutation in AGL gene in Tunisian patients with a glycogen storage disease type III: evidence of a founder effect.
A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series.
A mutation analysis of the AGL gene in Korean patients with glycogen storage disease type III.
A nonsense mutation due to a single base insertion in the 3'-coding region of glycogen debranching enzyme gene associated with a severe phenotype in a patient with glycogen storage disease type IIIa.
A novel donor splice site mutation in the glycogen debranching enzyme gene is associated with glycogen storage disease type III.
A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme.
A Novel Nonsense Mutation of the AGL Gene in a Romanian Patient with Glycogen Storage Disease Type IIIa.
A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb.
A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease.
A single-base deletion in the 3'-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients.
Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa.
Biochemical and molecular investigation of two Korean patients with glycogen storage disease type III.
Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency.
Cognitive profile of patients with glycogen storage disease type III: a clinical description of seven cases.
Compound heterozygous patient with glycogen storage disease type III: identification of two novel AGL mutations, a donor splice site mutation of Chinese origin and a 1-bp deletion of Japanese origin.
Distinct Clinical and Genetic Findings in Iranian Patients With Glycogen Storage Disease Type 3.
Distinct mutations in the glycogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions.
DNA-based subtyping of glycogen storage disease type III: mutation and haplotype analysis of the AGL gene in Chinese.
Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time.
Expression of a Functional Recombinant Human Glycogen Debranching Enzyme (hGDE) in N. benthamiana Plants and in Hairy Root Cultures.
Expression of catalytically active human multifunctional glycogen-debranching enzyme and lysosomal acid alpha-glucosidase in insect cells.
Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease.
Glucose-free/high-protein diet improves hepatomegaly and exercise intolerance in glycogen storage disease type III mice.
Glycogen Debrancher Enzyme Deficiency Myopathy.
Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features.
Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?
Glycogen storage disease type III: A novel Agl knockout mouse model.
Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.
Glycogen storage disease type IIIa presenting as non-ketotic hypoglycemia: use of a newly approved commercially available mutation analysis to non-invasively confirm the diagnosis.
Glycogen storage disease type IIIa: first report of a causative missense mutation (G1448R) of the glycogen debranching enzyme gene found in a homozygous patient.
High frequency of W1327X mutation in glycogen storage disease type III patients from central Tunisia.
Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III.
Intron retention is among six unreported AGL mutations identified in Malaysian GSD III patients.
Involvement of glycogen debranching enzyme in bladder cancer.
Isolation and nucleotide sequence of human liver glycogen debranching enzyme mRNA: identification of multiple tissue-specific isoforms.
Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa.
Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey.
Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with Glycogen Storage Disease Type III.
Molecular and biochemical characterization of a novel intronic single point mutation in a Tunisian family with glycogen storage disease type III.
Molecular and biochemical characterization of Tunisian patients with glycogen storage disease type III.
Molecular characterization of glycogen storage disease type III.
Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.
Multidisciplinary management of an obstetric patient with glycogen storage disease type 3.
Mutation Analysis in Glycogen Storage Disease Type III Patients in the Netherlands: Novel Genotype-Phenotype Relationships and Five Novel Mutations in the AGL Gene.
Mutational analysis of the AGL gene: five novel mutations in GSD III patients.
Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III.
Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle.
Polymorphic markers of the glycogen debranching enzyme gene allowing linkage analysis in families with glycogen storage disease type III.
Prenatal diagnosis and carrier detection for glycogen storage disease type III using polymorphic DNA markers.
Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis.
Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.
Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.
Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III.
Two new mutations in the 3' coding region of the glycogen debranching enzyme in a glycogen storage disease type IIIa Ashkenazi Jewish patient.
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]
[Glycogen debranching enzyme deficiency (Forbes-Cori disease)]
[Glycogen debranching enzyme deficiency]
Graft vs Host Disease
Isoamylase levels in bone marrow transplant patients are affected by total body irradiation and not by graft-versus-host disease.
Hepatitis
Mild pancreatic damage in acute viral hepatitis.
Serum isoamylases in acute and chronic liver disease.
Hepatitis, Chronic
Serum isoamylases in acute and chronic liver disease.
Hepatomegaly
A Japanese patient with cardiomyopathy caused by a novel mutation R285X in the AGL gene.
Glucose-free/high-protein diet improves hepatomegaly and exercise intolerance in glycogen storage disease type III mice.
Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]
Hyperlipidemias
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]
Hypoglycemia
A Japanese patient with cardiomyopathy caused by a novel mutation R285X in the AGL gene.
Glucose-free/high-protein diet improves hepatomegaly and exercise intolerance in glycogen storage disease type III mice.
Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]
Infections
Amylases of the genital tract. II. Peritoneal fluid isoamylases in acute salpingitis.
Irritable Bowel Syndrome
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
isoamylase deficiency
Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency.
Distinct Clinical and Genetic Findings in Iranian Patients With Glycogen Storage Disease Type 3.
Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time.
Glucose-free/high-protein diet improves hepatomegaly and exercise intolerance in glycogen storage disease type III mice.
Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features.
Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.
Severe acute pancreatitis and normal serum amylase activity due to pancreatic isoamylase deficiency.
[Glycogen debranching enzyme deficiency (Forbes-Cori disease)]
[Glycogen debranching enzyme deficiency]
Kidney Failure, Chronic
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Immunoreactive trypsin and pancreatic isoamylase activity in serum of patients with chronic renal failure or hepatic cirrhosis.
Pancreatic enzymes in patients with end-stage renal disease maintained on hemodialysis.
Pancreatic-type hyperamylasemia in end-stage renal disease.
Serum amylase and isoamylase in chronic renal failure.
Serum isoamylase measurements in pancreatitis complicating chronic renal failure.
The value of alpha-amylase and isoamylase determination in chronic renal failure patients.
Liver Cirrhosis
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Immunoreactive trypsin and pancreatic isoamylase activity in serum of patients with chronic renal failure or hepatic cirrhosis.
Serum isoamylases in acute and chronic liver disease.
Liver Cirrhosis, Biliary
The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis.
Liver Diseases
A cause of hyperamylasemia associated with chronic liver disease.
Hyperamylasemia with an abnormal isoamylase distribution in patients with liver diseases.
Serum isoamylases in acute and chronic liver disease.
Serum isoamylases in liver diseases.
Lung Neoplasms
Amylase in the lung.
Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth.
Salivary-type hyperamylasemia in primary lung cancer: observation of a possible precursor of the salivary-type isoamylase.
Unusual isomaylase in cancer-associated hyperamylasemia.
Lupus Erythematosus, Systemic
Systemic lupus erythematosus presenting initially with acute pancreatitis and a review of the literature.
Multiple Myeloma
[Tumor producing amylase]
Mumps
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Muscle Weakness
Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.
Muscular Diseases
Efficacy of cornstarch therapy in type III glycogen-storage disease.
Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.
Myocardial Infarction
Combination of miglitol, an anti-diabetic drug, and nicorandil markedly reduces myocardial infarct size through opening the mitochondrial K(ATP) channels in rabbits.
Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits.
Neoplasms
alpha-Amylase in resectable lung cancer.
Amylase producing lung cancer. Electronmicroscopical and biochemical studies.
Elevated activity of pancreatic type amylase in the urine as an early indicator of pancreatic tumors in hamsters.
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary.
Metabolic phenotype of bladder cancer.
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report.
Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease.
Salivary-type hyperamylasemia in primary lung cancer: observation of a possible precursor of the salivary-type isoamylase.
Studies of the effects of radiation or surgery on the salivary amylase activity and the isoamylase composition in salivary gland tumours.
Targeting glycogen metabolism in bladder cancer.
Tumor-associated hyperamylasemia.
Unusual anodic migrating isoamylase differentiates selected malignant from nonmalignant ascites.
[Clinical aspects and therapy of parotid tumors]
Obesity
Preferential salivary-type hypoamylasemia in obese children.
Ovarian Neoplasms
[Changes in activity of alpha amylase and its salivary isoenzyme in serum and urine after surgical treatment of ovarian neoplasms]
[Tumor producing amylase]
Pancreatic Cyst
Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease.
Pancreatic Diseases
Assessment of a rapid pancreatic isoamylase assay as a screening test for chronic pancreatic disease.
Clinical application of organ specific isoamylases.
Clinical significance of serum pancreatic enzymes in the quiescent phase of chronic pancreatitis.
Comparative study of serum pancreatic isoamylase, lipase, and trypsin-like immunoreactivity in pancreatic disease.
Concentration of immunoreactive trypsin and activity of pancreatic isoamylase in serum compared in pancreatic diseases.
Diagnostic utility of a new monoclonal antibody pancreatic isoamylase assay in chronic pancreatic diseases.
Diagnostic value of serum elastase 1 in pancreatic disease.
Fecal isoamylase activity in patients with pancreatic diseases.
Isoamylase determination by isoelectric focusing in pancreatic disorders. A potential clinical aid.
Isoamylases in pancreatic carcinoma and chronic relapsing pancreatitis.
Macroamylasemia and other chronic nonspecific hyperamylasemias: chemical oddities or clinical entities?
Relation of electrophoretic pattern of amylase isoenzymes to severity of pancreatic disease.
Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease.
Sensitivity and specificity of canine serum total amylase and isoamylase activity determinations.
Serum amylase and isoamylase values in dogs with pancreatic disease.
Serum isoamylase activities in pancreatic diseases.
Serum isoamylase pattern in obstructive pancreatic disease.
Serum levels of six pancreatic enzymes as related to the degree of renal dysfunction.
Serum pancreatic isoamylase activity in pancreatic disease.
[Immunotrypsinogen and amylase isoenzymes in pancreatic diseases]
[Serum pancreatic secretory trypsin inhibitor (PSTI), amylase activity and pancreatic isoamylase activity in pancreatic diseases]
Pancreatic Neoplasms
Comparative study of serum pancreatic isoamylase, lipase, and trypsin-like immunoreactivity in pancreatic disease.
Diagnostic utility of a new monoclonal antibody pancreatic isoamylase assay in chronic pancreatic diseases.
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Fecal isoamylase activity in patients with pancreatic diseases.
Serum phospholipase A2 activity in chronic pancreatic diseases.
Structure of a polysaccharide from Gastrodia elata Bl., and oligosaccharides prepared thereof with anti-pancreatic cancer cell growth activities
Urinary phospholipase A2 excretion in chronic pancreatic diseases.
[Serum pancreatic enzymes in the diagnosis of carcinoma of the pancreas]
Pancreatic Pseudocyst
Isoamylase pattern diagnostic of pancreatic pseudocyst.
Isoamylases and their thermolability in serum and cyst fluid from patients with pancreatic pseudocysts.
Pancreatic pseudocyst associated with eating disorder.
Puzzling persistent hyperamylasemia, probably neither pancreatic nor pathologic.
Serum pancreatic isoamylase activity in pancreatic disease.
Pancreatitis
A correlation between clinical pancreatitis and isoenzyme patterns of amylase.
Acute alcohol intoxication: significance of the amylase level.
Alcohol Abuse and Pancreatic Diseases: An Overview.
Alcoholic pancreatitis and parotitis: utility of lipase and urinary amylase clearance determinations.
Amylase isoenzymes in the acute abdomen: an adjunct in those patients with elevated total amylase.
Amylase, lipase, pancreatic isoamylase, and phospholipase A in diagnosis of acute pancreatitis.
Amylase-creatinine clearance ratios and serum amylase isoenzymes in moderate renal insufficiency.
Clinical validity of a continuous colorimetric method for serum lipase.
Clinical value of routine isoamylase analysis of hyperamylasemia.
Comparative study of serum pancreatic isoamylase, lipase, and trypsin-like immunoreactivity in pancreatic disease.
Comparison of serum amylase pancreatic isoamylase and lipase in patients with hyperamylasemia.
Correlation of pancreatic enzyme levels with the patient's recovery from acute edematous pancreatitis.
Diagnostic assays in acute pancreatitis. A study of sensitivity and specificity.
Diagnostic value of routine isoamylase assay of hyperamylasemic serum.
Diagnostic value of serum elastase 1 in pancreatic disease.
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Diseased dogs isoamylases in clinically normal and diseased dogs.
Does subclinical pancreatic inflammation occur after parathyroidectomy?
Effects of ischemia on the human pancreas.
Evaluation and comparison of cathodic trypsin-like immunoreactivity, pancreatic lipase and pancreatic isoamylase in the diagnosis of acute pancreatitis in 849 consecutive patients with acute abdominal pain.
Exocrine pancreatic function (serum immunoreactive trypsin, fecal chymotrypsin, and pancreatic isoamylase) in Indian diabetics.
Fecal isoamylase activity in patients with pancreatic diseases.
Hyperamylasemia after cardiac surgery. Incidence, significance, and management.
Isoamylase levels in bone marrow transplant patients are affected by total body irradiation and not by graft-versus-host disease.
Mechanism of increased renal clearnace of amylase/creatinine in acute pancreatitis.
Multicenter evaluation of a specific pancreatic isoamylase assay based on a double monoclonal-antibody technique.
Nonpancreatic-type hyperamylasemia associated with pancreatic cancer.
Pancreatic enzymes in chronic renal failure.
Pancreatic enzymes in patients with end-stage renal disease maintained on hemodialysis.
Pancreatitis-like isoamylase pattern in normal persons.
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report.
Radioimmunoassay for human pancreatic lipase in acute pancreatitis.
Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease.
Sensitivity and specificity of canine serum total amylase and isoamylase activity determinations.
Serum amylase and isoamylases and their origins in healthy dogs and dogs with experimentally induced acute pancreatitis.
Serum amylase, isoamylase, and lipase in the acute abdomen. Their diagnostic value for acute pancreatitis.
Serum isoamylase measurements in pancreatitis complicating chronic renal failure.
Serum pancreatic enzyme assays in acute abdomen: a comparative prospective study.
Serum pancreatic enzyme behavior during the course of acute pancreatitis.
Serum pancreatic isoamylase activity in pancreatic disease.
Serum tests for pancreatitis in patients with abdominal pain.
Severe acute pancreatitis and normal serum amylase activity due to pancreatic isoamylase deficiency.
Studies on serum amylase in normal man and in acute pancreatitis.
Systemic lupus erythematosus presenting initially with acute pancreatitis and a review of the literature.
The pancreatic enzymes value in the diagnosis of acute pancreatitis and acute biliary tract diseases.
The role of serum isoamylase and lipase determinations in clinical practice.
Time course of changes in serum activity of the P3 isoform of pancreatic amylase isoenzyme in patients with acute pancreatitis.
Use of amylase isoenzymes in laboratory evaluation of hyperamylasemia.
Value of the P3 amylase fraction as an indicator of the long-term prognosis of acute pancreatitis.
What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study.
Where does serum amylase come from and where does it go?
[A study of lipase, amylase and isoamylase in acute pancreatitis]
[Diagnostic value of a diagnostic strip for determining urinary amylase]
[Diagnostic value of lipase and isoamylase determination. Monitoring studies in patients with proven and suspected pancreatitis]
[Diagnostic value of various laboratory parameters in acute pancreatitis]
[Importance of the delay in the serum determination of amylase, lipase and isoamylase P3 in the diagnosis of acute pancreatitis]
[Significance of immunoreactive lipase in the diagnosis of pancreatic diseases]
[Significance of serum levels of elastase 1 and pancreatic isoamylase in acute and chronic recurrent pancreatitis]
Pancreatitis, Alcoholic
Alcoholic pancreatitis and parotitis: utility of lipase and urinary amylase clearance determinations.
Clinical value of serum pancreatic enzymes in acute alcohol intoxication and acute alcoholic pancreatitis.
Pancreatitis, Chronic
A preliminary report on urinary BT-PABA/PAS excretion index, serum pancreatic isoamylase and faecal chymotrypsin tests of pancreatic dysfunction in Sowetan Africans.
Assessment of a rapid pancreatic isoamylase assay as a screening test for chronic pancreatic disease.
Behaviour of serum pancreatic enzymes in chronic pancreatitis.
Clinical significance of serum pancreatic enzymes in the quiescent phase of chronic pancreatitis.
Comparative study of serum pancreatic isoamylase, lipase, and trypsin-like immunoreactivity in pancreatic disease.
Diagnostic utility of a new monoclonal antibody pancreatic isoamylase assay in chronic pancreatic diseases.
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
Effect of secretin upon the levels of pancreatic enzymes in blood serum.
Fecal isoamylase activity in patients with pancreatic diseases.
Isoamylase determination by isoelectric focusing in pancreatic disorders. A potential clinical aid.
Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease.
Serum amylase isozymes in patients with chronic pancreatitis with hyperamylasemia.
Serum cathodic trypsin-like immunoreactivity, pancreatic lipase, and pancreatic isoamylase as diagnostic tests of chronic pancreatitis or pancreatic steatorrhea.
Serum immunoreactive trypsin, pancreatic polypeptide, and pancreatic isoamylase as diagnostic tests for chronic pancreatitis.
Serum pancreatic isoamylase estimation by the inhibitor method as a diagnostic test for chronic pancreatitis.
Serum phospholipase A2 activity in chronic pancreatic diseases.
Urinary phospholipase A2 excretion in chronic pancreatic diseases.
Value of pancreatic-type isoamylase assay as an index of pancreatic insufficiency.
[Occurrence and nature of hyperamylasemia in chronic alcoholics]
[Serum pancreatic enzymes in the diagnosis of carcinoma of the pancreas]
Parotid Diseases
[Clinical aspects and therapy of parotid tumors]
Peptic Ulcer
Differential determination of serum isoamylase using an amylase inhibitor and its clinical application.
The clinical significance of salivary amylase in duodenal aspirates in evaluation of exocrine pancreas function.
Pleural Effusion
A prospective study of amylase-rich pleural effusions with special reference to amylase isoenzyme analysis.
Pneumonia
Amylase in the lung.
Pregnancy, High-Risk
High-risk pregnancies and amniotic fluid isoamylase activity.
Proteinuria
Assessment of glomerular charge selectivity in man by differential clearance of isoamylases.
Renal Insufficiency
Amylase and isoamylase activities in renal insufficiency.
Immunoreactive trypsin and pancreatic isoamylase activity in serum of patients with chronic renal failure or hepatic cirrhosis.
P3 isoamylase accompanying renal insufficiency.
Serum isoamylase measurements in pancreatitis complicating chronic renal failure.
Sialadenitis
Correlation between postsialographical changes of salivary isoamylase levels in serum and histopathological findings in sublingual glands in patients with Sjögren's syndrome.
Steatorrhea
Comparative diagnostic accuracy of four tubeless pancreatic function tests in chronic pancreatitis.
Estimation of serum pancreatic isoamylase: its role in the diagnosis of exocrine pancreatic insufficiency.
Isoamylase determination by isoelectric focusing in pancreatic disorders. A potential clinical aid.
Serum cathodic trypsin-like immunoreactivity, pancreatic lipase, and pancreatic isoamylase as diagnostic tests of chronic pancreatitis or pancreatic steatorrhea.
Urinary Bladder Neoplasms
CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL).
Involvement of glycogen debranching enzyme in bladder cancer.
Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.
Targeting glycogen metabolism in bladder cancer.
Ventricular Dysfunction, Left
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction.